KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exact Sciences (EXAS) Non-Current Deffered Revenue: 2010-2012

Historic Non-Current Deffered Revenue for Exact Sciences (EXAS) over the last 2 years, with Dec 2012 value amounting to $295,000.

  • Exact Sciences' Non-Current Deffered Revenue fell 93.35% to $295,000 in Q4 2012 from the same period last year, while for Dec 2012 it was $295,000, marking a year-over-year decrease of 93.35%. This contributed to the annual value of $295,000 for FY2012, which is 93.35% down from last year.
  • Exact Sciences' Non-Current Deffered Revenue amounted to $295,000 in Q4 2012, which was down 77.84% from $1.3 million recorded in Q3 2012.
  • Over the past 5 years, Exact Sciences' Non-Current Deffered Revenue peaked at $8.6 million during Q4 2010, and registered a low of $295,000 during Q4 2012.
  • In the last 3 years, Exact Sciences' Non-Current Deffered Revenue had a median value of $3.9 million in 2011 and averaged $4.1 million.
  • Data for Exact Sciences' Non-Current Deffered Revenue shows a maximum YoY tumbled of 93.35% (in 2012) over the last 5 years.
  • Over the past 3 years, Exact Sciences' Non-Current Deffered Revenue (Quarterly) stood at $8.6 million in 2010, then tumbled by 48.28% to $4.4 million in 2011, then plummeted by 93.35% to $295,000 in 2012.
  • Its Non-Current Deffered Revenue stands at $295,000 for Q4 2012, versus $1.3 million for Q3 2012 and $2.4 million for Q2 2012.